Clinical trial
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With…
NCT00089427 · INSYS Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00089427 |
|---|---|
| Title | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma |
| Official title | Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma |
| Lead sponsor | INSYS Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma |
| Intervention type | Drug, Procedure |
| Interventions | IL13-PE38QQR, Surgery for placement, Radiation therapy, Temozolomide with radiation therapy |
| Enrollment | 24 |
| Start date | Jul 1, 2004 |
| Primary completion | Jul 1, 2007 |
| First posted | Aug 6, 2004 |
| Last update posted | Jul 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: